168 related articles for article (PubMed ID: 38553708)
21. Single-cell immunophenotyping revealed the association of CD4+ central and CD4+ effector memory T cells linking exacerbating chronic obstructive pulmonary disease and NSCLC.
Gémes N; Balog JÁ; Neuperger P; Schlegl E; Barta I; Fillinger J; Antus B; Zvara Á; Hegedűs Z; Czimmerer Z; Manczinger M; Balogh GM; Tóvári J; Puskás LG; Szebeni GJ
Front Immunol; 2023; 14():1297577. PubMed ID: 38187374
[TBL] [Abstract][Full Text] [Related]
22. Correlation between the Treg/Thl7 Index and the Efficacy of PD-1 Monoclonal Antibody in Patients with Advanced Non-Small-Cell Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease.
Wang X; She X; Gao W; Liu X; Shi B
Comput Math Methods Med; 2022; 2022():2923998. PubMed ID: 35915772
[TBL] [Abstract][Full Text] [Related]
23. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
24. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
Zhu X; Sun L; Song N; He W; Xie B; Hu J; Zhang J; Yang J; Dai J; Bian D; Xia H; Sun F; Xiong A; Luo J; Zhang L; Yu H; Liu M; Liu H; Wang H; Zhang H; Chen C; Wu C; Duan L; Zhu Y; Zhang P; Jiang G
BMC Med; 2022 Dec; 20(1):493. PubMed ID: 36581917
[TBL] [Abstract][Full Text] [Related]
25. Treatment response and safety of immunotherapy for advanced non-small cell lung cancer with comorbid chronic obstructive pulmonary disease: a retrospective cohort study.
Zhang K; Zhou C; Gao J; Yu P; Lin X; Xie X; Liu M; Zhang J; Xie Z; Cui F; Li S; Passiglia F; Stella GM; Qin Y
Transl Lung Cancer Res; 2022 Nov; 11(11):2306-2317. PubMed ID: 36519030
[TBL] [Abstract][Full Text] [Related]
26. Dynamic
Chen ZY; Fu R; Tan XY; Yan LX; Tang WF; Qiu ZB; Qi YF; Li YF; Hou QY; Wu YL; Zhong WZ; Jiang BY
Thorac Cancer; 2022 Sep; 13(17):2524-2531. PubMed ID: 35822254
[TBL] [Abstract][Full Text] [Related]
27. Immunosuppression by Inflammation-Stimulated Amplification of Myeloid-Derived Suppressor Cells and Changes in Expression of Immune Checkpoint HHLA2 in Chronic Obstructive Pulmonary Disease.
Xu L; Li F; Jiang M; Li Z; Xu D; Jing J; Wang J; Ding J
Int J Chron Obstruct Pulmon Dis; 2023; 18():139-153. PubMed ID: 36846109
[TBL] [Abstract][Full Text] [Related]
28. Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
Biton J; Ouakrim H; Dechartres A; Alifano M; Mansuet-Lupo A; Si H; Halpin R; Creasy T; Bantsimba-Malanda C; Arrondeau J; Goldwasser F; Boudou-Rouquette P; Fournel L; Roche N; Burgel PR; Goc J; Devi-Marulkar P; Germain C; Dieu-Nosjean MC; Cremer I; Herbst R; Damotte D
Am J Respir Crit Care Med; 2018 Oct; 198(7):928-940. PubMed ID: 29518341
[TBL] [Abstract][Full Text] [Related]
29. Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study.
She Y; He B; Wang F; Zhong Y; Wang T; Liu Z; Yang M; Yu B; Deng J; Sun X; Wu C; Hou L; Zhu Y; Yang Y; Hu H; Dong D; Chen C; Tian J
EBioMedicine; 2022 Dec; 86():104364. PubMed ID: 36395737
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
Jia XH; Xu H; Geng LY; Jiao M; Wang WJ; Jiang LL; Guo H
Lung Cancer; 2020 Sep; 147():143-153. PubMed ID: 32717571
[TBL] [Abstract][Full Text] [Related]
31. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
Weissferdt A; Pataer A; Vaporciyan AA; Correa AM; Sepesi B; Moran CA; Wistuba II; Roth JA; Shewale JB; Heymach JV; Kalhor N; Cascone T; Hofstetter WL; Lee JJ; Swisher SG
Clin Lung Cancer; 2020 Jul; 21(4):341-348. PubMed ID: 32279936
[TBL] [Abstract][Full Text] [Related]
32. Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD.
Suzuki Y; Inui N; Karayama M; Imokawa S; Yamada T; Yokomura K; Asada K; Kusagaya H; Kaida Y; Matsuda H; Koshimizu N; Toyoshima M; Masuda M; Hayakawa H; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Suda T
Int J Chron Obstruct Pulmon Dis; 2019; 14():1867-1877. PubMed ID: 31686799
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
[TBL] [Abstract][Full Text] [Related]
34. Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients.
Zhou Z; Ding Z; Yuan J; Shen S; Jian H; Tan Q; Yang Y; Chen Z; Luo Q; Cheng X; Yu Y; Niu X; Qian L; Chen X; Gu L; Liu R; Ma S; Huang J; Chen T; Li Z; Ji W; Song L; Shen L; Jiang L; Yu Z; Zhang C; Tai Z; Wang C; Chen R; Carbone DP; Xia X; Lu S
J Hematol Oncol; 2022 May; 15(1):62. PubMed ID: 35585646
[TBL] [Abstract][Full Text] [Related]
35. Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations.
Lim JU; Yeo CD; Rhee CK; Kim YH; Park CK; Kim JS; Kim JW; Lee SH; Kim SJ; Yoon HK; Kim TJ; Lee KY
PLoS One; 2015; 10(11):e0142306. PubMed ID: 26555338
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the molecular expression profile of non small cell lung carcinoma associated to chronic obstructive pulmonary disease.
Garcia-Lujan R; Conde-Gallego E; Lopez-Ríos F; Martin de Nicolas JL; Sanchez-Céspedes M; García-Quero C; Echave-Sustaeta JM; Lopez-Encuentra A
Histol Histopathol; 2009 Apr; 24(4):417-23. PubMed ID: 19224444
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study.
Dai F; Wu X; Wang X; Li K; Wang Y; Shen C; Zhou J; Niu H; Deng B; Tan Q; Wang R; Guo W
Front Oncol; 2022; 12():1022123. PubMed ID: 36353552
[TBL] [Abstract][Full Text] [Related]
38. Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
Zhang C; Hong HZ; Wu YL; Zhong WZ
JTCVS Open; 2021 Dec; 8():588-607. PubMed ID: 36004199
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY
Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945
[TBL] [Abstract][Full Text] [Related]
40. Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial.
Zhao J; Zhao L; Guo W; Wang S; Tao X; Li L; Mao Y; Tan F; Gao Y; Wu N; Ying J; Xue Q; Li N; Gao S; He J
J Thorac Oncol; 2023 Jun; 18(6):780-791. PubMed ID: 36870519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
